vs
阿帕奇（LASE）与Prime Medicine, Inc.（PRME）财务数据对比。点击上方公司名可切换其他公司
阿帕奇的季度营收约是Prime Medicine, Inc.的1.1倍（$919.3K vs $838.0K），阿帕奇净利率更高（-506.4% vs -5498.7%，领先4992.2%），阿帕奇同比增速更快（28.3% vs -61.6%）
IPG光子公司是光纤激光器制造商，研发并商业化推广光纤激光器产品，其产品广泛应用于材料加工、医疗、电信等多个领域，目前在美国、德国、俄罗斯和意大利均设有生产基地。
Prime Medicine, Inc.是一家总部位于美国马萨诸塞州剑桥的生物科技企业，核心业务是依托先导编辑技术开发新型基因治疗方案，致力于为遗传病等相关疾病探索创新治疗手段，推动前沿基因编辑技术的临床转化与应用。
LASE vs PRME — 直观对比
营收规模更大
LASE
是对方的1.1倍
$838.0K
营收增速更快
LASE
高出89.9%
-61.6%
净利率更高
LASE
高出4992.2%
-5498.7%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $919.3K | $838.0K |
| 净利润 | $-4.7M | $-46.1M |
| 毛利率 | -20.1% | — |
| 营业利润率 | -350.0% | -5800.5% |
| 净利率 | -506.4% | -5498.7% |
| 营收同比 | 28.3% | -61.6% |
| 净利润同比 | -186.5% | -9.0% |
| 每股收益（稀释后） | $-0.27 | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LASEPRME
| Q4 25 | — | $838.0K | ||
| Q3 25 | $919.3K | $1.2M | ||
| Q2 25 | $2.6M | $1.1M | ||
| Q1 25 | $2.3M | $1.5M | ||
| Q4 24 | $1.3M | $2.2M | ||
| Q3 24 | $716.7K | — | ||
| Q2 24 | $623.4K | $0 | ||
| Q1 24 | $743.0K | $591.0K |
净利润LASEPRME
| Q4 25 | — | $-46.1M | ||
| Q3 25 | $-4.7M | $-50.6M | ||
| Q2 25 | $-1.8M | $-52.6M | ||
| Q1 25 | $-1.7M | $-51.9M | ||
| Q4 24 | $586.4K | $-42.3M | ||
| Q3 24 | $-1.6M | — | ||
| Q2 24 | $-934.3K | $-55.3M | ||
| Q1 24 | $-545.7K | $-45.8M |
毛利率LASEPRME
| Q4 25 | — | — | ||
| Q3 25 | -20.1% | — | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | 49.8% | — | ||
| Q4 24 | 13.3% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 50.6% | — | ||
| Q1 24 | 51.9% | — |
营业利润率LASEPRME
| Q4 25 | — | -5800.5% | ||
| Q3 25 | -350.0% | -4406.0% | ||
| Q2 25 | -37.0% | -4787.2% | ||
| Q1 25 | -68.7% | -3603.3% | ||
| Q4 24 | -255.1% | -2025.7% | ||
| Q3 24 | -238.0% | — | ||
| Q2 24 | -149.4% | — | ||
| Q1 24 | -73.8% | -8179.5% |
净利率LASEPRME
| Q4 25 | — | -5498.7% | ||
| Q3 25 | -506.4% | -4129.1% | ||
| Q2 25 | -68.3% | -4716.7% | ||
| Q1 25 | -73.4% | -3568.8% | ||
| Q4 24 | 45.7% | -1936.6% | ||
| Q3 24 | -226.8% | — | ||
| Q2 24 | -149.9% | — | ||
| Q1 24 | -73.4% | -7743.0% |
每股收益（稀释后）LASEPRME
| Q4 25 | — | $-0.22 | ||
| Q3 25 | $-0.27 | $-0.32 | ||
| Q2 25 | $-0.12 | $-0.41 | ||
| Q1 25 | $-0.12 | $-0.40 | ||
| Q4 24 | $0.06 | $-0.31 | ||
| Q3 24 | $-0.13 | — | ||
| Q2 24 | $-0.09 | $-0.46 | ||
| Q1 24 | $-0.06 | $-0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.6M | $63.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.1M | $120.9M |
| 总资产 | $17.5M | $342.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LASEPRME
| Q4 25 | — | $63.0M | ||
| Q3 25 | $3.6M | $71.4M | ||
| Q2 25 | $78.5K | $53.8M | ||
| Q1 25 | $179.1K | $91.9M | ||
| Q4 24 | $533.9K | $182.5M | ||
| Q3 24 | $2.1M | — | ||
| Q2 24 | $2.7M | $55.6M | ||
| Q1 24 | $5.2M | $94.2M |
股东权益LASEPRME
| Q4 25 | — | $120.9M | ||
| Q3 25 | $4.1M | $161.8M | ||
| Q2 25 | $4.3M | $60.9M | ||
| Q1 25 | $6.8M | $106.9M | ||
| Q4 24 | $10.2M | $153.1M | ||
| Q3 24 | $9.7M | — | ||
| Q2 24 | $10.3M | $196.6M | ||
| Q1 24 | $12.4M | $243.8M |
总资产LASEPRME
| Q4 25 | — | $342.7M | ||
| Q3 25 | $17.5M | $385.0M | ||
| Q2 25 | $14.9M | $279.0M | ||
| Q1 25 | $16.0M | $328.2M | ||
| Q4 24 | $17.2M | $297.5M | ||
| Q3 24 | $10.6M | — | ||
| Q2 24 | $11.1M | $259.7M | ||
| Q1 24 | $13.6M | $311.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $763.1K | $-37.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-37.5M |
| 自由现金流率自由现金流/营收 | — | -4480.4% |
| 资本支出强度资本支出/营收 | — | 34.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-167.1M |
8季度趋势，按日历期对齐
经营现金流LASEPRME
| Q4 25 | — | $-37.3M | ||
| Q3 25 | $763.1K | $-35.0M | ||
| Q2 25 | $-1.0M | $-41.4M | ||
| Q1 25 | $-1.2M | $-48.9M | ||
| Q4 24 | $-6.5M | $16.2M | ||
| Q3 24 | $632.7K | — | ||
| Q2 24 | $-2.4M | $-45.5M | ||
| Q1 24 | $-866.3K | $-67.7M |
自由现金流LASEPRME
| Q4 25 | — | $-37.5M | ||
| Q3 25 | — | $-35.3M | ||
| Q2 25 | — | $-43.0M | ||
| Q1 25 | — | $-51.3M | ||
| Q4 24 | — | $14.5M | ||
| Q3 24 | $589.6K | — | ||
| Q2 24 | $-2.4M | $-47.4M | ||
| Q1 24 | $-1.0M | $-70.0M |
自由现金流率LASEPRME
| Q4 25 | — | -4480.4% | ||
| Q3 25 | — | -2880.5% | ||
| Q2 25 | — | -3855.1% | ||
| Q1 25 | — | -3526.8% | ||
| Q4 24 | — | 662.1% | ||
| Q3 24 | 82.3% | — | ||
| Q2 24 | -388.0% | — | ||
| Q1 24 | -136.9% | -11849.6% |
资本支出强度LASEPRME
| Q4 25 | — | 34.6% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 141.0% | ||
| Q1 25 | — | 166.6% | ||
| Q4 24 | — | 82.0% | ||
| Q3 24 | 6.0% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 20.3% | 393.2% |
现金转化率LASEPRME
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -11.11× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
